9.20
Schlusskurs vom Vortag:
$9.21
Offen:
$9.2
24-Stunden-Volumen:
1.12M
Relative Volume:
1.11
Marktkapitalisierung:
$636.37M
Einnahmen:
$202.09M
Nettoeinkommen (Verlust:
$-61.69M
KGV:
-8.5185
EPS:
-1.08
Netto-Cashflow:
$-35.64M
1W Leistung:
-4.37%
1M Leistung:
+0.11%
6M Leistung:
-16.67%
1J Leistung:
-16.97%
Evolus Inc Stock (EOLS) Company Profile
Firmenname
Evolus Inc
Sektor
Telefon
(949) 284-4555
Adresse
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
Vergleichen Sie EOLS mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
EOLS
Evolus Inc
|
9.20 | 636.37M | 202.09M | -61.69M | -35.64M | -1.08 |
![]()
RGC
Regencell Bioscience Holdings Ltd
|
14.60 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
![]()
ZTS
Zoetis Inc
|
159.19 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
HLN
Haleon Plc Adr
|
10.35 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
15.37 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.64 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-04-17 | Eingeleitet | BTIG Research | Buy |
2024-01-29 | Hochstufung | Barclays | Equal Weight → Overweight |
2022-06-23 | Eingeleitet | Needham | Buy |
2022-05-12 | Hochstufung | Barclays | Underweight → Equal Weight |
2022-01-20 | Hochstufung | Truist | Hold → Buy |
2021-05-06 | Hochstufung | Mizuho | Neutral → Buy |
2021-04-08 | Bestätigt | H.C. Wainwright | Buy |
2021-02-24 | Herabstufung | Truist | Buy → Hold |
2020-07-07 | Herabstufung | Mizuho | Buy → Neutral |
2020-02-06 | Fortgesetzt | Mizuho | Buy |
2019-11-26 | Eingeleitet | SVB Leerink | Outperform |
2019-09-05 | Fortgesetzt | Mizuho | Buy |
2019-06-28 | Eingeleitet | Wells Fargo | Market Perform |
2019-06-11 | Eingeleitet | Barclays | Underweight |
2019-03-20 | Eingeleitet | SunTrust | Buy |
2019-02-14 | Eingeleitet | H.C. Wainwright | Buy |
2019-01-29 | Eingeleitet | Stifel | Buy |
Alle ansehen
Evolus Inc Aktie (EOLS) Neueste Nachrichten
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 13, 2025 - BioSpace
(EOLS) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | EOLS Stock News - GuruFocus
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
Midday Stock Roundup: Xponential Fitness Down, Yoshiharu Up - Orange County Business Journal
Evolus Inc (EOLS) Stock Price Up 3.95% on Jun 11 - GuruFocus
Insider Spends US$189k Buying More Shares In Evolus - simplywall.st
Insider Buying: White Albert G III Acquires 20,000 Shares of Evolus Inc (EOLS) - GuruFocus
EOLS Director Boosts Stake with Significant Share Purchase | EOLS Stock News - GuruFocus
Evolysse™ Recognized in 2025 Shape Skin Awards | EOLS Stock News - GuruFocus
Evolysse™ Recognized in 2025 Shape Skin Awards - Yahoo Finance
Evolus, Inc. (NASDAQ:EOLS) Holdings Lowered by Squarepoint Ops LLC - Defense World
Evolus Announces Board Changes and Director Elections - TipRanks
Evolus, Inc. (EOLS) Stock Analysis: A 142% Potential Upside Sparks Investor Interest - DirectorsTalk Interviews
Evolus, Inc. (NASDAQ:EOLS) Shares Acquired by Bank of America Corp DE - Defense World
EOLS Set to Participate in BTIG's Virtual Meeting on June 9 | EO - GuruFocus
Evolus, Inc. (NASDAQ:EOLS) Shares Bought by Ameriprise Financial Inc. - Defense World
EOLS Set to Participate in BTIG's Virtual Meeting on June 9 | EOLS Stock News - GuruFocus
Evolus Launches Second Product Line for Wrinkles - Orange County Business Journal
ProShare Advisors LLC Grows Stock Holdings in Evolus, Inc. (NASDAQ:EOLS) - Defense World
Evolus boosts balance sheet with lower-cost refinancing and flexibility - MSN
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $347,000 Stock Position in Evolus, Inc. (NASDAQ:EOLS) - Defense World
Evolus announces CFO resignation - MSN
Stifel maintains Evolus stock buy rating, $25 target - Investing.com Australia
Stifel maintains Evolus stock buy rating, $25 target By Investing.com - Investing.com Nigeria
Increases to CEO Compensation Might Be Put On Hold For Now at Evolus, Inc. (NASDAQ:EOLS) - simplywall.st
Mizuho maintains Evolus stock Outperform rating and $25 target By Investing.com - Investing.com India
Evolus CFO Sandra Beaver resigns for new role By Investing.com - Investing.com South Africa
Mizuho maintains Evolus stock Outperform rating and $25 target - Investing.com
Evolus CFO to Resign - Orange County Business Journal
Evolus CFO Sandra Beaver Resigns - MarketScreener
Evolus (EOLS) CFO Resignation Announced - GuruFocus
Evolus CFO Sandra Beaver resigns for new role - Investing.com India
Evolus CFO Sandra Beaver Announces Resignation - TipRanks
Resignation of CFO Impacts Evolus (EOLS) Leadership | EOLS Stock News - GuruFocus
Evolus Announces Departure of its Chief Financial Officer | EOLS Stock News - GuruFocus
Evolus announces departure of CFO Sandra Beaver - TipRanks
Evolus Announces Departure Of Its Chief Financial Officer - marketscreener.com
Evolus Announces Departure of its Chief Financial Officer - Business Wire
BNP Paribas Financial Markets Has $400,000 Stock Holdings in Evolus, Inc. (NASDAQ:EOLS) - Defense World
Evolysse HA gels outperform Restylane in clinical study - Investing.com Australia
Evolus Announces Publication of U.S. Pivotal Study for Evolysse Form and Evolysse Smooth Injectable Hyaluronic Acid Gels - marketscreener.com
Evolus announces publication of U.S. pivotal study for Evolysse injectable gels - TipRanks
EOLS Publishes Promising Study Results on Evolysse Injectable Gels | EOLS Stock News - GuruFocus
Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels - BioSpace
Evolysse HA gels outperform Restylane in clinical study By Investing.com - Investing.com Canada
Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ - GuruFocus
Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels | EOLS Stock News - GuruFocus
Trend Tracker for (EOLS) - news.stocktradersdaily.com
Deutsche Bank AG Cuts Stock Holdings in Evolus, Inc. (NASDAQ:EOLS) - Defense World
Comerica Bank Purchases New Stake in Evolus, Inc. (NASDAQ:EOLS) - Defense World
Finanzdaten der Evolus Inc-Aktie (EOLS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Evolus Inc-Aktie (EOLS) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
MOATAZEDI DAVID | See Remarks |
Jun 16 '25 |
Sale |
9.89 |
16,582 |
164,054 |
364,927 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):